Cycloalkano[b]pyridines as ActiVe ORL1 Antagonists
Journal of Medicinal Chemistry, 2008, Vol. 51, No. 13 4029
ization through antisense mapping of a k3-related opioid receptor. Mol.
Pharmacol. 1995, 47, 1180–1188.
(13) Kawamoto, H.; Ozaki, S.; Itoh, Y.; Miyaji, M.; Arai, S.; Nakashima,
H.; Kato, T.; Ohta, H.; Iwasawa, Y. Discovery of the first potent and
selective small molecule opioid receptor-like (ORL1) antagonist:
1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-
1,3-dihydro-2H-benzimidazol-2-one (J-113397). J. Med. Chem. 1999,
42, 5061–5063.
(14) Kobayashi, K.; Takahashi, H.; Kawamoto, H.; Kato, T.; Itoh, S.;
Yoshizumi, T.; Okamoto, O. Preparation of benzimidazole derivatives
as therapeutic agents with high affinity for nociceptin receptor. WO
2003095432, 2003.
(15) Kobayashi, K.; Uchiyama, M.; Takahashi, H.; Kawamoto, H.; Ito, S.;
Yoshizumi, T.; Nakashima, H.; Kato, T.; Shimizu, A.; Miyazoe, H.;
Asai, M.; Ohno, A.; Hirayama, M.; Ozaki, S.; Tani, T.; Tanaka, T.;
Mochidome, T.; Tadano, K.; Takahiro, F.; Okamoto, O.; Ohta, H.
Optimization of a benzimidazole series as opioid receptor-like 1
(ORL1) antagonists. Abstracts of Papers, 232nd ACS National
Meeting, San Francisco, CA, Sept 10-14, 2006.
(16) Niiyama, K.; Mase, T.; Takahashi, H.; Naya, A.; Katsuki, K.; Nagase,
T.; Ito, S.; Hayama, T.; Hisaka, A.; Ozaki, S.; Ihara, M.; Yano, M.;
Fukuroda, T.; Noguchi, K.; Nishikibe, M.; Ishikawa, K. 6-Carboxy-
5,7-diarylcyclopenteno[1,2-b]pyridine derivatives: a novel class of
endothelin receptor antagonists. Bioorg. Med. Chem. 2002, 10, 2461–
2470.
(17) Yoshizumi, T.; Miyazoe, H.; Sugimoto, Y.; Takahashi, H.; Okamoto,
O. An efficient and convenient synthesis of tetrahydrocycloheptapy-
ridines: new precursors for CNS agents. Synthesis 2005, 10, 1593–
1600.
(18) The absolute configuration was determined by an asymmetric synthesis
of (-)-18, unpublished results.
(19) Using the anomalous dispersion effect, the refinement of the crystal
structure model provided an unambiguous determination of the absolute
configuration of compound (-)-10l. The crystal structure results for
compound 10l have been deposited with the CCDC as CCDC 682100.
These data can be obtained free of charge from The Cambridge
cif.
(20) Kozikowski, A. P.; Araldi, G. L.; Boja, J.; Meil, W. M.; Johnson,
K. M.; Flippen-Anderson, J. L.; George, C.; Saiah, E. Chemistry and
pharmacology of the piperidine-based analogues of cocaine. Identifica-
tion of potent DAT inhibitors lacking the tropane skeleton. J. Med.
Chem. 1998, 41, 1962–1969.
(21) Eastwood, P. R. A versatile synthesis of 4-aryl tetrahydropiridines
via palladium mediated Suzuki cross-coupling with cyclic vinyl
boronates. Tetrahedron Lett. 2000, 41, 3705–3708.
(22) Ozaki, S.; Kawamoto, H.; Itoh, Y.; Miyaji, M.; Azuma, T.; Ichikawa,
D.; Nambu, H.; Iguchi, T.; Iwasawa, Y.; Ohta, H. In vitro and in vivo
pharmacological characterization of J-113397, a potent and selective
non-peptidyl ORL1 receptor antagonist. Eur. J. Pharamacol. 2000,
402, 45–53.
(23) (a) Lynch, J. J., Jr.; Wallance, A. A.; Stupienski, R. F., III; Baskin,
E. P.; Beare, C. M.; Appleby, S. D.; Salata, J. J.; Jurkiewicz, N. K.;
Sanguinetti, M. C.; Stein, R. B.; Gehret, J. R.; Kothstein, T.; Claremon,
D. A.; Elliott, J. M.; Butcher, J. W.; Remy, D. C.; Baldwin, J. J.
Cardiac electrophysiologic and antiarrhythmic actions of two long-
acting spirobenzopyran piperidine class III agents, L-702,958 and
L-706,000 [MK-499]. J. Pharmacol. Exp. Ther. 1994, 269, 541–553.
(b) Butcher, J. W.; Claremon, D. A.; Connolly, T. M.; Dean, D. C.;
Karczewski, J.; Koblan, K. S.; Kostura, M. J.; Liverton, N. J.; Melillo,
D. G. Radioligand and binding Assay. World Patent Application WO
200205860, 2002.
(24) The enantiomer of 2b was 4.5 times less potent than 2b.
(25) Rizzi, A.; Gavioli, E. C.; Marzona, G.; Spangnolo, B.; Zucchini, S.;
Ciccocioppo, R.; Trapella, C.; Regoli, D.; Calo`, G. Pharmacological
characterization of the nociceptin/orphanin FQ receptor antagonist SB-
612111: in vivo studies. J. Pharmacol. Exp. Ther. 2007, 321, 968–
974.
(2) (a) Reinsceid, R. K.; Nothacker, H.-P.; Bourson, A.; Ardati, A.;
Henningsen, R. A.; Bunzow, J. R.; Grady, D. K.; Langen, H.; Monsma,
F. J., Jr.; Civelli, O. Orphanin FQ: a neuropeptide that activates an
opioid like G protein-coupled receptor. Science 1995, 270, 792–794.
(b) Meunier, J.-C.; Mollereau, C.; Toll, L.; Suaudeu, C.; Moisand,
C.; Alvinerie, P.; Butour, J.-L.; Guillemot, J.-C.; Ferrara, P.; Monsarrat,
B.; Mazarguil, H.; Vassart, G.; Parmentier, M.; Constentin, J. Isolation
and structure of the endogenous agonist of opioid receptor-like ORL-1
receptor. Nature 1995, 377, 532–535.
(3) Mogil, J. S.; Grisel, J. E.; Reinscheid, R. K.; Civelli, O.; Belknap,
J. K.; Grandy, D. K. Orphanin FQ is a functional anti-opioid peptide.
Neuroscience (Oxford) 1996, 75, 333–337.
(4) (a) Manabe, T.; Noda, Y.; Mamiya, T.; Katagiri, H.; Houtani, T.; Nishi,
M.; Noda, T.; Takahashi, T.; Sugimoto, T.; Nabeshima, T.; Takeshima,
H. Facilitation of long-term potentiation and memory in mice lacking
nociceptin receptors. Nature (London) 1998, 394 (6693), 577–581.
(b) Sandin, J.; Georgieva, J.; Schott, P. A.; Orgen, S. O.; Terenius, L.
Nociceptin/Orphanin FQ microinjected into hippocampus impairs
spinal learning in rats. Eur. J. Neurosci. 1997, 9, 194–197. (c) Yu,
T. P.; Fein, J.; Phan, T.; Evans, C. J.; Xie, C.-W. Orphanin FQ inhibits
synaptic transmission and long-term protection in rat hippocampus.
Hippocampus 1997, 7, 88–94.
(5) Pomonis, J. D.; Billington, C. J.; Levine, A. S. Orphanin FQ, agonist
of orphan opioid receptor ORL-1, stimulates feeding in rats. Neu-
roReport 1996, 8, 369–371.
(6) Jenck, F.; Moreau, J.-L.; Martin, J. R.; Kilpatrick, G. J.; Reinscheid,
R. K.; Monsma, F. J., Jr.; Nothacker, H.-P.; Civelli, O. Orphanin FQ
acts as an anxiolytic to attenuate behavioral response to stress. Proc.
Natl. Acad. Sci. U.S.A. 1997, 94, 14854–14858.
(7) (a) Champion, H. C.; Katwitz, P. J. Nociceptin, an endogenous ligand
for ORL1 receptor, has novel hypotensive activity in the rat. Life Sci.
1997, 60, 241–245. (b) Gumusel, B.; Hao, Q.; Hyman, A.; Chang,
J.-K.; Kapusta, D. R.; Lippton, H. Nociceptin: an endogenous agonist
for central opioid like 1 (ORL1) receptors possesses systemic
vasorelaxant properties. Life Sci. 1997, 60, 141–145.
(8) Champion, H. C.; Wang, R.; Hellstrom, W. J. G.; Kadowitz, P. J.
Nociceptin, a novel endogenous ligand for ORL1 receptor, has potent
erectile activity in the cat. Am. J. Physiol. 1997, 273, E214–E219.
(9) (a) Chiou, L. -C.; Liao, Y. -Y.; Fan, P. -C.; Kuo, P. -H.; Wang, C.
-H.; Riemer, C.; Prinssen, E. P. Nociceptin/Orphanin FQ peptide
receptors: pharmacology and clinical implications. Curr. Drug Targets
2007, 8, 117–135. (b) Bignan, G. C.; Connolly, P. J.; Middleton, S. A.
Recent advances towards the discovery of ORL-1 receptor agonists
and antagonists. Expert Opin. Ther. Patents 2005, 15, 357–388. (c)
Zaveri, N. Peptide and nonpeptide ligands for the nociceptin/orphanin
FQ receptor ORL1: research tools and potential therapeutic agents.
Life Sci. 2003, 73, 663–678. (d) Ronzoni, S.; Peretto, I.; Giardina,
G. A. M. Lead generation and lead optimization approaches in the
discovery of selective, non-peptide ORL-1 receptor agonists and
antagonists. Expert Opin. Ther. Patents 2001, 11, 525–546.
(10) Shinkai, H.; Ito, T.; Iida, T.; Kitano, Y.; Yamada, H.; Uchida, I.
4-Aminoquinolines: Novel nociceptin antagonists with analgesic
activity. J. Med. Chem. 2000, 43, 4667–4677.
(11) Zaratin, P. F.; Petrone, G.; Sbacchi, M.; Garnier, M.; Fossati, C.;
Petrillo, P.; Ronzoni, S.; Giardina, G. A. M.; Scheideler, M. A.
Modification of nociceptin and morphine tolerance by the selective
ORL-1 antagonist SB-612111. J. Pharmacol. Exp. Ther. 2004, 308,
454–461.
(12) (a) Goto, Y.; Arai-Otsuki, S.; Tachibana, Y.; Ichikawa, D.; Ozaki, S.;
Takahashi, H.; Iwasawa, Y.; Okamoto, O.; Okuda, S.; Ohta, H.; Sagara,
T. Identification of a novel spiropiperidine opioid receptor-like 1
antagonist class by a focused library approach featuring 3D-pharma-
cophore similarity. J. Med. Chem. 2006, 49, 847–849. (b) Arai, T.;
Nishikimi, Y.; Imamura, S.; Kamiyama, K.; Kobayashi, M. Preparation
of spiro compounds as nociceptin receptor binders. WO 200226714,
2002. (c) Ito, F.; Koike, H.; Sudo, M.; Yamagishi, T.; Ando, K.
Preparation of spiropiperidine compounds as ligands for the ORL-1
receptor. WO 2003000677, 2003.
(26) Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal
chemistry of hERG optimizations: highlights and hang-ups. J. Med.
Chem. 2006, 49, 1–17.
JM701590H